Biotechnology company and global drug delivery platform
innovator Lexaria Bioscience
Corp. (CSE: LXX) (OTCQX: LXRP) today announced its receipt of a new
patent granted in Australia: #2016367037 / Grant Date August 15, 2019 – “Stable
ready-to-drink beverage compositions comprising lipophilic active agents.”
According to the update, this increases Lexaria’s portfolio to 16 awarded
patents protecting its DehydraTECH(TM) drug delivery platform, with eight in the
USA and eight in Australia. The new Australian patent, together with Australian
Patent #2016367036 announced on August 15, 2019, are the first granted in
Lexaria’s second and third patent families that differ from the company’s
original patent family, “Food and beverage compositions infused with lipophilic
active agents and methods of use thereof.” These new patents include claims for
DehydraTECH technology with respect to food and beverage use and also, for the
first time, for pharmaceutical applications for delivery of cannabinoids as
methods of treating certain conditions. These include, but are not limited to
heart disease, neurological diseases, obesity, metabolic and appetite
disorders, hepatic diseases, diabetes, cancer via chemotherapy, irritable bowel
syndrome (“IBS”), marijuana abuse, and opioid, alcohol, nicotine or cocaine
addiction.
To view the full press releases, visit http://ibn.fm/JemJa
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its
DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
